In contrast to CYP2C19, the CYP3A5*3 genotype did not affect the clearance of zonisamide, indicating that CYP3A5*3 genotypes do not have a major impact on the zonisamide pharmacokinetics in Japanese patients with epilepsy. The gene discussed is CYP2C19; the disease is epilepsy.